RxDoctor Payments Data

Michael Cromer, MD

Family Medicine · Tampa, FLNPI 1326006081

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $481 of the $631 with a category attached, or 76.2%. 10 manufacturers reported payments, led by AbbVie at 29.0% of the total.

$631in general payments, 2019–2025

Across 15 payments — averaging $42.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$183
  • Galderma Laboratories, L.p.$150
  • Abbott$99
  • Dexcom, Inc.$90
  • Novo Nordisk$31
  • Sanofi-aventis U.S. LLC$20
  • plus $58 from 4 others
$484,150in research payments, 2019–2025

Across 5 payments — averaging $96,830 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$484K

What the payments were for

  • Speaking & faculty fees$15024%
  • Food & beverage$48176%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$631 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$96,825
Medicare patients
317
Services billed
3,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$158,312
OzempicSemaglutide104$127,292
JardianceEmpagliflozin54$63,658
XareltoRivaroxaban50$60,735
BiktarvyBictegrav/Emtricit/Tenofov Ala12$55,369
MounjaroTirzepatide50$55,251
JanuviaSitagliptin Phosphate46$45,644
TrulicityDulaglutide32$35,586
Breo ElliptaFluticasone/Vilanterol46$22,464
Spiriva RespimatTiotropium Bromide33$22,157
LinzessLinaclotide26$22,059
ProliaDenosumab11$19,347
EntrestoSacubitril/Valsartan17$18,409
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,462
FarxigaDapagliflozin Propanediol16$15,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$127,292104 claims
Johnson & JohnsonXarelto$14$60,73550 claims
AbbVieLinzess, Synthroid$183$25,83081 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tampa

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →